摘要
Objective:We analyzed the relationship between the expression of ERCC-1(excisition repair cross complement-1), survivin and sensitivity and prognosis of cisplatin contained regimens first-line chemotherapy in advanced lung adenocarcinoma.Methods:Immunohistochemical(IHC) method was used to evaluate the expression of ERCC-1 and survivin in 80 pathologically confirmed advanced lung adenocarcinoma patients given cisplatin-contained regimens first-line chemotherapy.The response rate and survival time were analyzed according to the expression of ERCC-1 and survivin.Results:Only 77 patients could be reviewed by IHC staining.The expression rates of ERCC-1 and survivin were 33.77% and 53.25 % respectively.The worse response rate and shorter TTP/ PFS could be identified in ERCC-1 positive group.Patients with positive expression of survivin had worse survival time.Conclusion:Expression of ERCC-1 may be a molecular marker of cisplatincontained regimens first-line chemotherapy resistance and poor prognosis in advanced lung adenocarcinoma patients.Positive expression of survivin predicates poor prognosis for patients with advanced lung adenocarcinoma.
Objective： We analyzed the relationship between the expression of ERCC-1 （excisition repair cross complement- 1）, survivin and sensitivity and prognosis of cisplatin contained regimens first-line chemotherapy in advanced lung adenocarcinoma. Methods： Immunohistochemical （IHC） method was used to evaluate the expression of ERCC-1 and survivin in 80 pathologically confirmed advanced lung adenocarcinoma patients given cisplatin-contained regimens first-line chemotherapy. The response rate and survival time were analyzed according to the expression of ERCC-1 and survivin. Results： Only 77 patients could be reviewed by IHC staining. The expression rates of ERCC-1 and survivin were 33.77% and 53.25 % respectively. The worse response rate and shorter TTP/PFS could be identified in ERCC-1 positive group. Patients with positive expression of survivin had worse survival time. Conclusion： Expression of ERCC-1 may be a molecular marker of cispla- tincontained regimens first-line chemotherapy resistance and poor prognosis in advanced lung adenocarcinoma patients. Positive expression of survivin predicates poor prognosis for patients with advanced lung adenocarcinoma.
基金
Supported by a grant from the Science and Technology Key Project of Henan Province (No. 200538).
